MRNS vs. RAPT, PBYI, AKBA, NBTX, URGN, ANRO, RVNC, KMDA, FBLG, and VNDA
Should you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include RAPT Therapeutics (RAPT), Puma Biotechnology (PBYI), Akebia Therapeutics (AKBA), Nanobiotix (NBTX), UroGen Pharma (URGN), Alto Neuroscience (ANRO), Revance Therapeutics (RVNC), Kamada (KMDA), FibroBiologics (FBLG), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Marinus Pharmaceuticals (NASDAQ:MRNS) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
In the previous week, Marinus Pharmaceuticals had 13 more articles in the media than RAPT Therapeutics. MarketBeat recorded 13 mentions for Marinus Pharmaceuticals and 0 mentions for RAPT Therapeutics. Marinus Pharmaceuticals' average media sentiment score of 0.00 equaled RAPT Therapeutics'average media sentiment score.
RAPT Therapeutics has lower revenue, but higher earnings than Marinus Pharmaceuticals. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Marinus Pharmaceuticals received 338 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 69.27% of users gave Marinus Pharmaceuticals an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 5.5% of Marinus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
RAPT Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -513.80%. RAPT Therapeutics' return on equity of -72.61% beat Marinus Pharmaceuticals' return on equity.
Marinus Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
Marinus Pharmaceuticals currently has a consensus target price of $13.79, suggesting a potential upside of 806.95%. RAPT Therapeutics has a consensus target price of $24.67, suggesting a potential upside of 542.36%. Given Marinus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Marinus Pharmaceuticals is more favorable than RAPT Therapeutics.
Summary
Marinus Pharmaceuticals beats RAPT Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Marinus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marinus Pharmaceuticals Competitors List
Related Companies and Tools
